Different from TLR agonists, inhibitors of indoleamine 2,3-dioxygenase (IDO) can block important negative regulatory molecules overexpressed in tumor cells and antigen-presenting cells (Peng et al., 2018). Here, IDO1 is linked to neoplasm.